Dear Reader,

The current issue features several articles in the category *Novel Vaccines*: a review on assessing clinical efficacy of asexual blood-stage malaria vaccines (Sheehy, p), protective-antigen-based anthrax vaccines conferring protection against inhalation anthrax (Merkel, p), immunization with OM-85 BV to prevent respiratory infections in HIV-positive patients (Capetti, p), a Phase 2 clinical trial of heat-killed *Mycobacterium vaccae* formulated as an oral pill (Efremenko, p), naturally occurring IgG antibody levels to the *Staphylococcus aureus* protein IsdB in humans (Zorman, p), and two commentaries discussing the possibility of a universal *S. aureus* vaccine (Pier, p) and the making of vaccines *on demand* as a potential solution for emerging pathogens and biodefense (De Groot, p).

The section *Licensed Vaccines* contains a review on passive immunization for the public health control of communicable diseases (Young, p), a product review on hexavalent IPV-based combination vaccines (Mahmood, p), and studies on immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in Indian infants (Eregowda, p), pre-exposure prophylaxis against rabies in children (Ravish, p), feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies (Madhusudana, p), and seroprevalence of antibodies against measles, rubella, mumps, varicella, and pertussis in young adults in Spain (González-Escalada, p).

One paper related to *Vaccine Acceptance* investigates knowledge and attitudes of postpartum women toward immunization during pregnancy and the peripartum period (Rossmann Beel, p), and the section *Health Economics* features a review on economic evaluation of Varicella vaccination (Unim, p). The rubric *Public Programs* has one paper looking at immunization services offered in pharmacies (Sauvageau, p). A commentary on particle-based vaccine formulations for transcutaneous immunization (Mittal, p) is featured in the category *Technologies*, and another commentary related to *Immunotherapy* discusses interleukin-15-differentiated dendritic cells as vaccine candidates for cancer immunotherapy (Anguille, p).

Several papers in this issue deal with different aspects of *Influenza*, such as intranasal vaccination with an inactivated whole virus vaccine (Ainai, p), immunogenicity and safety of Intanza/IDflu intradermal vaccine (Hoon Han, p), immunogenicity of a trivalent inactivated seasonal vaccine in children (Pavia-Ruz, p), and concerns for low coverage of influenza vaccination in middle-aged adults (Lee, p).

One paper in the section *Rotavirus* looks at comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles (Lappalainen, p), and one paper on *Hepatitis* investigates anti-HBs antibody levels after hepatitis B vaccination in diabetic children and adolescents (Elrashidy, p).

Finally, we are pleased to present a series of meeting reports on some of the most important conferences related to vaccines and immunotherapeutics. Four reports cover selected topics presented at the recent meeting Modern Vaccine/Adjuvant Formulation (May 2013, Lausanne, Switzerland), including vaccine and adjuvant formulation and production (Fox, p), nanoparticle-based vaccine adjuvants (Tupin, p), the need for vaccine improvement and for adjuvant development (Dalençon, p), and challenges and promises of the field of vaccine adjuvants (Collin, p). One report from the annual World Vaccine Congress (April 2013, Washington DC, USA) discusses cancer vaccines in the immunotherapy era (Kim, p). The great challenges involved in working in emerging markets (Valencia, p and Onraedt, p.) are discussed in two reports from Phacilitate Partnering for Vaccine Emerging Markets (June 2013, Berlin, Germany). Finally, this section features a meeting report on CIMT 2013, the annual meeting of the Association for Immunotherapy of Cancer (May 2013, Mainz, Germany) (Diken, p).

Your suggestions for future meeting reports are welcome. Simply contact the Acquisitions Editor Eva Riedmann (eva\@landesbioscience.com).

Our monthly News, Policy and Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. In our NP&P track we also regularly present companies and organizations related to vaccines and immunotherapy. Furthermore, this section regularly features commentaries on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Please contact Eva Riedmann (eva\@landesbioscience.com) if you would like to contribute to our NP&P track in a future issue of *HV&I*.

Finally, we want to draw your attention to several popular website features, which is usuable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a *HV&I* facebook account for daily updates.

Sincerely,

Ronald Ellis, PhD

Editor-in-Chief

Eva M Riedmann, PhD

Acquisitions Editor
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